The data suggest that SGLT1 has clinical utility for DCM diagnosis, and SGLT1 inhibition can attenuate apoptosis to suppress the development of DCM via the JNK and p38 pathway, potentially providing a promising treatment for DCM. The gene discussed is MAPK14; the disease is familial dilated cardiomyopathy.